OSE Immunotherapeutics SA (EPA:OSE)
France · Delayed Price · Currency is EUR 3.024
-0.050 (-1.63%)
Apr 24, 2026, 5:35 PM CET
OSE Immunotherapeutics Earnings Call Transcripts
Fiscal Year 2025
-
A new management team has launched a strategic plan focused on maximizing value from Tedopi and Lusvertikimab, with four key levers and a balanced financial strategy targeting EUR 90 million over three years. Clinical progress and partnership discussions are ongoing, with a focus on market-driven formulations and rare disease indications.